Chronic Hepatitis B Virus Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Ascletis Pharma, Shanghai HEP Pharma, Romark Laboratories, Qilu Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Hepatitis B Virus pipeline constitutes 55+ key companies continuously working towards developing 60+ Chronic Hepatitis B Virus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Hepatitis B Virus Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Hepatitis B Virus Market.

The Chronic Hepatitis B Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Hepatitis B Virus Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Chronic Hepatitis B Virus treatment therapies with a considerable amount of success over the years.

*
Chronic Hepatitis B Virus companies working in the treatment market are Arbutus Biopharma, GSK/Ionis Pharmaceuticals, Vir Biotechnology, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp, Brii Biosciences Limited, Vir Biotechnology, Inc., Arbutus Biopharma Corporation, Erasmus Medical Center, Daewoong Pharmaceutical Co., Ascletis Pharmaceuticals, Gilead Sciences, Fujian Akeylink Biotechnology, Chia Tai Tianqing Pharma, Janssen Research & Development, LLC, Hoffmann-La Roche, Chengdu Suncadia Medicine, Suzhou Ribo Life Science, Arbutus Biopharma Corporation, Ascentage Pharma Group, and others, are developing therapies for the Chronic Hepatitis B Virus treatment

*
Emerging Chronic Hepatitis B Virus therapies in the different phases of clinical trials are- AB-729, Bepirovirsen, Elebsiran, GSK3965193, DA-2803, ChAdOx1-HBV, Undiluted I.V.-Hepabig inj(GC5103), PEG-IFN, VIR-3434, AB-729, ISA104, Vemliver tablet, ASC22, TAF, GST-HG131, TQA3605 tablets, JNJ-73763989, Nucleos(t)ide (NUC), HRS9950 tablets, RBD1016, Imdusiran, APG-1387, and others are expected to have a significant impact on the Chronic Hepatitis B Virus market in the coming years.

*
For Imdusiran (AB-729), the primary endpoints included the incidence and severity of treatment-emergent adverse events (TEAEs), discontinuations due to adverse events (AEs), and lab abnormalities following treatment with AB-729 plus Peg-IFN-2a.

*
The main endpoint for GSK3228836 (Bepirovirsen) is the proportion of participants achieving a functional cure (FC) with baseline HBsAg less than or equal to 3000 IU/mL.

*
In July 2025, TherVacB, an innovative therapeutic vaccine for chronic hepatitis B developed by Helmholtz Munich in partnership with the German Center for Infection Research (DZIF), has advanced into its first patient clinical trial. After completing a successful Phase Ia study in healthy volunteers-showing good safety and promising immune responses-the program has now moved into a multi-center Phase Ib/IIa trial, with the first patient enrolled in June 2025.

*
In June 2025, TherVacB, an innovative therapeutic vaccine for chronic hepatitis B developed by Helmholtz Munich in partnership with the German Center for Infection Research (DZIF), began its first clinical trial in patients. After a successful Phase Ia trial in healthy volunteers, which showed a favorable safety profile and induced the intended immune responses, the study has advanced to a multi-center Phase Ib/IIa trial, with the first patient enrolled in June 2025.

*
In May 2025, interim data from a Phase 2b clinical trial showed that AHB-137, Ausperbio's investigational therapy, safely and effectively suppressed the hepatitis B virus (HBV) in individuals with chronic hepatitis B. These encouraging results, consistent with earlier findings from an ongoing Phase 1/2a trial (NCT06115993), were presented during a poster session at the annual European Association for the Study of the Liver Congress.

*
In May 2025, Vir Biotechnology's combination therapy aimed at a "functional cure" for hepatitis B did not meet efficacy endpoints in a Phase II trial. Data from the 24-week mark of the ongoing MARCH Phase II study (NCT04856085) showed that only 17% (3/18) of patients receiving tobevibart and elebsiran alone, and 21% (3/14) of those receiving the combination with peginterferon, achieved undetectable hepatitis B surface antigen (HBsAg) among patients with baseline HBsAg



This release was published on openPR.